Literature DB >> 20110370

Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1.

Victoria Prieto-Echagüe1, Azad Gucwa, Barbara P Craddock, Deborah A Brown, W Todd Miller.   

Abstract

Ack1 is a nonreceptor tyrosine kinase that participates in tumorigenesis, cell survival, and migration. Relatively little is known about the mechanisms that regulate Ack1 activity. Recently, four somatic missense mutations of Ack1 were identified in cancer tissue samples, but the effects on Ack1 activity, and function have not been described. These mutations occur in the N-terminal region, the C-lobe of the kinase domain, and the SH3 domain. Here, we show that the cancer-associated mutations increase Ack1 autophosphorylation in mammalian cells without affecting localization and increase Ack1 activity in immune complex kinase assays. The cancer-associated mutations potentiate the ability of Ack1 to promote proliferation and migration, suggesting that point mutation is a mechanism for Ack1 deregulation. We propose that the C-terminal Mig6 homology region (MHR) (residues 802-990) participates in inhibitory intramolecular interactions. The isolated kinase domain of Ack1 interacts directly with the MHR, and the cancer-associated E346K mutation prevents binding. Likewise, mutation of a key hydrophobic residue in the MHR (Phe(820)) prevents the MHR-kinase interaction, activates Ack1, and increases cell migration. Thus, the cancer-associated mutation E346K appears to destabilize an autoinhibited conformation of Ack1, leading to constitutively high Ack1 activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110370      PMCID: PMC2856269          DOI: 10.1074/jbc.M109.060459

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

Review 1.  The conformational plasticity of protein kinases.

Authors:  Morgan Huse; John Kuriyan
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

2.  The SAM domain of polyhomeotic forms a helical polymer.

Authors:  Chongwoo A Kim; Mari Gingery; Rosemarie M Pilpa; James U Bowie
Journal:  Nat Struct Biol       Date:  2002-06

3.  Crystal structures of the phosphorylated and unphosphorylated kinase domains of the Cdc42-associated tyrosine kinase ACK1.

Authors:  Julie C Lougheed; Rui-Hong Chen; Polly Mak; Thomas J Stout
Journal:  J Biol Chem       Date:  2004-08-11       Impact factor: 5.157

Review 4.  Regulation of protein kinases; controlling activity through activation segment conformation.

Authors:  Brad Nolen; Susan Taylor; Gourisankar Ghosh
Journal:  Mol Cell       Date:  2004-09-10       Impact factor: 17.970

5.  A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42.

Authors:  E Manser; T Leung; H Salihuddin; L Tan; L Lim
Journal:  Nature       Date:  1993-05-27       Impact factor: 49.962

6.  Regulation of c-Src tyrosine kinase activity by the Src SH2 domain.

Authors:  X Liu; S R Brodeur; G Gish; Z Songyang; L C Cantley; A P Laudano; T Pawson
Journal:  Oncogene       Date:  1993-05       Impact factor: 9.867

7.  Tyrosine phosphorylation of ACK in response to temperature shift-down, hyperosmotic shock, and epidermal growth factor stimulation.

Authors:  T Satoh; J Kato; K Nishida; Y Kaziro
Journal:  FEBS Lett       Date:  1996-05-20       Impact factor: 4.124

8.  Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck.

Authors:  Noriko Yokoyama; W Todd Miller
Journal:  J Biol Chem       Date:  2003-09-22       Impact factor: 5.157

9.  Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells.

Authors:  G T Hoehn; T Stokland; S Amin; M Ramírez; A L Hawkins; C A Griffin; D Small; C I Civin
Journal:  Oncogene       Date:  1996-02-15       Impact factor: 9.867

10.  Structural basis for the autoinhibition of c-Abl tyrosine kinase.

Authors:  Bhushan Nagar; Oliver Hantschel; Matthew A Young; Klaus Scheffzek; Darren Veach; William Bornmann; Bayard Clarkson; Giulio Superti-Furga; John Kuriyan
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

View more
  20 in total

1.  FRK suppresses the proliferation of human glioma cells by inhibiting cyclin D1 nuclear accumulation.

Authors:  Lei Hua; Ming Zhu; Xu Song; Jun Wang; Zhen Fang; Chunting Zhang; Qiong Shi; Wenjian Zhan; Lei Wang; Qingming Meng; Xiuping Zhou; Rutong Yu
Journal:  J Neurooncol       Date:  2014-05-03       Impact factor: 4.130

2.  ACK1 upregulated the proliferation of head and neck squamous cell carcinoma cells by promoting p27 phosphorylation and degradation.

Authors:  Hsuan-Hsiang Peng; Hao-Chin Yang; Darius Rupa; Chun-Han Yen; Ya-Wen Chiu; Wei-Jia Yang; Fuh-Jinn Luo; Ta-Chun Yuan
Journal:  J Cell Commun Signal       Date:  2022-03-05       Impact factor: 5.782

3.  Regulation of Ack1 localization and activity by the amino-terminal SAM domain.

Authors:  Victoria Prieto-Echagüe; Azad Gucwa; Deborah A Brown; W Todd Miller
Journal:  BMC Biochem       Date:  2010-10-27       Impact factor: 4.059

Review 4.  ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  Cancer Lett       Date:  2013-04-15       Impact factor: 8.679

5.  UHMK1 promotes gastric cancer progression through reprogramming nucleotide metabolism.

Authors:  Xing Feng; Dong Ma; Jiabao Zhao; Yongxi Song; Xuehui Hong; Zhiyong Zhang; Yuekun Zhu; Qingxin Zhou; Fei Ma; Xing Liu; Mengya Zhong; Yu Liu; Yubo Xiong; Xingfeng Qiu; Zhen Zhang; Heng Zhang; Yongxiang Zhao; Kaiguang Zhang
Journal:  EMBO J       Date:  2020-01-23       Impact factor: 11.598

6.  Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.

Authors:  Chelsea Jenkins; Samuel B Luty; Julia E Maxson; Christopher A Eide; Melissa L Abel; Corinne Togiai; Eneida R Nemecek; Daniel Bottomly; Shannon K McWeeney; Beth Wilmot; Marc Loriaux; Bill H Chang; Jeffrey W Tyner
Journal:  Sci Signal       Date:  2018-07-17       Impact factor: 8.192

7.  Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.

Authors:  Julia E Maxson; Melissa L Abel; Jinhua Wang; Xianming Deng; Sina Reckel; Samuel B Luty; Huahang Sun; Julie Gorenstein; Seamus B Hughes; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Jerald Radich; Oliver Hantschel; Richard E Middleton; Nathanael S Gray; Brian J Druker; Jeffrey W Tyner
Journal:  Cancer Res       Date:  2015-12-17       Impact factor: 12.701

8.  Activated Cdc42-associated kinase 1 (Ack1) is required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor recruitment to lipid rafts and induction of cell death.

Authors:  Emma Linderoth; Giulia Pilia; Nupam P Mahajan; Ingvar Ferby
Journal:  J Biol Chem       Date:  2013-10-01       Impact factor: 5.157

9.  Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer.

Authors:  Kiran Mahajan; Domenico Coppola; Bhupendra Rawal; Y Ann Chen; Harshani R Lawrence; Robert W Engelman; Nicholas J Lawrence; Nupam P Mahajan
Journal:  J Biol Chem       Date:  2012-05-07       Impact factor: 5.157

10.  Proximity-Dependent Biotinylation to Elucidate the Interactome of TNK2 Nonreceptor Tyrosine Kinase.

Authors:  Raiha Tahir; Anil K Madugundu; Savita Udainiya; Jevon A Cutler; Santosh Renuse; Li Wang; Nicole A Pearson; Christopher J Mitchell; Nupam Mahajan; Akhilesh Pandey; Xinyan Wu
Journal:  J Proteome Res       Date:  2021-08-24       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.